Ian Wilcox

Ian Wilcox

Auto-generated profile, based on publicly available information

Ian Wilcox

Department of Medicine, University of Sydney, Australia

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2003 in JACC
Verified
Journal Article
Closed access
JLJ.O-Dee L Lattimore
J.O-Dee L Lattimore
DCDavid S Celermajer
David S Celermajer
IWIan Wilcox
Ian Wilcox

1 September 1993 in SLEEP
Verified
Journal Article
Open access
PDF file
IWIan Wilcox
Ian Wilcox
RGRonald R. Grunstein
Ronald R. Grunstein
JHJan A. Hedner
Jan A. Hedner
JDJean Doyle
Jean Doyle
FCFiona L. Collins
Fiona L. Collins
CSColin E. Sullivan
Colin E. Sullivan
Ambulatory blood pressure (BP) was measured noninvasively (Oxford Medilog ABP) at 15-minute intervals for 24 hours before and after 8 weeks of treatment with nasal continuous positive airway pressure (nCPAP) in 19 men with obstructive sleep apnea (OSA). We included both normotensive and hypertensive patients, but hypertensives were studied after withdrawal of antihypertensive drugs. Ambulatory BP before and after treatment was compared using patients as their own controls. Treatment with nCPAP was successfully established in 14 of the 19 patients (74%). Blood pressure fell significantly in patients who were successfully treated: 24-hour mean BP (systolic/diastolic) decreased from 141 ± 18/89 ± 11 mm Hg to 134 ± 19/85 ± 13 mm Hg (p < 0.05). The reduction in 24-hour mean systolic BP occurred during both day and night, but a significant fall in mean diastolic BP was only observed during the day. The mean blood pressure fell in both normotensive and hypertensive patients. Patients who were inadequately treated with nCPAP had no reduction in mean 24-hour BP. Effective treatment of sleep apnea with nCPAP was associated with a significant fall in both systolic and diastolic BP independent of changes in body weight or alcohol consumption, suggesting that sleep apnea was an independent factor contributing to elevated nighttime and daytime BP in these patients.

1 November 1992 in American Review of Respiratory Disease
Verified
Journal Article
Closed access
JHJan A. Hedner
Jan A. Hedner
IWIan Wilcox
Ian Wilcox
LLLeon Laks
Leon Laks
RGRon R. Grunstein
Ron R. Grunstein
CSColin E. Sullivan
Colin E. Sullivan
A hypoxic ramp test (to 75% arterial oxygen saturation) during the awake state was performed in 17 patients with obstructive sleep apnea (OSA). Blood pressure was monitored with an indwelling arterial line (radial artery), and the ventilatory response to eucapnic hypoxia was determined. Eight of the patients were normotensive. The remaining nine hypertensive patients were studied after a 3-wk washout of antihypertensive medication. Compared with a nonmatched group of normotensive nonsnoring control subjects in whom hypoxemia did not affect blood pressure, all OSA patients showed various degrees of pressor responses during hypoxia. The pressor response was of similar magnitude in normotensive and hypertensive patients with OSA. There was a significant relationship between the ventilatory and the pressor responses to hypoxia (p = 0.03) that was similar in both normotensive and hypertensive patients. Although disease severity expressed as apnea index (number of apneas per hour of sleep) or minimum arterial oxygen saturation reached during the overnight recording correlated with the magnitude of the pressor response (p = 0.03 and 0.045, respectively), the ventilatory response to hypoxia was unrelated to disease severity. Hypoxemia induced a similar increase in heart rate in controls and in normotensive patients, but an attenuated heart rate response was seen at the nadir of oxygen saturation in hypertensive subjects (p < 0.05). These data demonstrate that patients with obstructive sleep apneas have a pressor response to hypoxia. This response is likely to be involved in the blood pressure swings seen during apnea in patients with OSA. Although the magnitude of the pressor response was unrelated to resting blood pressure, this mechanism may contribute to the development of cardiovascular disease in patients With OSA.

1 June 2006 in Thorax
Verified
Journal Article
Open access
PDF file
JLJ L Lattimore
J L Lattimore
IWI Wilcox
I Wilcox
MSMichael R. Skilton
Michael R. Skilton
MLM Langenfeld
M Langenfeld
DCD S Celermajer
D S Celermajer
Background: Obstructive sleep apnoea (OSA) is a common and potentially reversible cause of systemic hypertension. The mechanisms whereby OSA leads to hypertension and the effects of treatment on arterial function, however, are not well established. Microvascular arterial endothelial and smooth muscle function was assessed in subjects with OSA before and after treatment with continuous positive airways pressure (CPAP). Methods: Ten subjects of mean (SE) age 49 (8) years with at least moderately severe OSA had detailed forearm vascular reactivity studies before and after 3 months of CPAP treatment. The systemic circulation was assessed by measuring brachial artery pressure, flow and resistance responses to intra-arterial infusions of acetylcholine (ACh; an endothelium dependent vasodilator), sodium nitroprusside (SNP; an endothelium independent vasodilator), l-NMMA (a nitric oxide (NO) antagonist), and l-arginine (the substrate for NO). Results: Before CPAP, ACh and SNP infusions increased forearm blood flow in a dose dependent manner (p<0.01). After CPAP, endothelium dependent dilation to ACh was significantly increased (434 (23)% of baseline after CPAP v 278 (20)% before CPAP, p<0.001), whereas SNP induced dilation was unchanged. Resting NO production was higher after CPAP, evidenced by a significantly greater reduction in basal flow by l-NMMA (p = 0.05). l-Arginine reversed the effect of l-NMMA in all cases. Conclusion: In patients with OSA, treatment with CPAP improves baseline endothelial NO release and stimulates endothelium dependent vasorelaxation in the systemic circulation. This is a potential mechanism for improving systemic and vascular function in patients with OSA treated with CPAP.

1 October 1989 in Clinical Science
Verified
Journal Article
Closed access
JKJ. Krieger
J. Krieger
LLL. Laks
L. Laks
IWI. Wilcox
I. Wilcox
RGR. R. Grunstein
R. R. Grunstein
LCL. J. V. Costas
L. J. V. Costas
CSC. E. Sullivan
C. E. Sullivan
1. Plasma levels of atrial natriuretic peptide (ANP) were measured in seven patients with obstructive sleep apnoea (OSA) while they were awake, during repetitive apnoea and during treatment with nasal continuous positive airway pressure (CPAP). 2. ANP levels in both pulmonary artery and peripheral venous samples were elevated during apnoeic sleep and reduced when apnoea was prevented by nasal CPAP. Mean values of pulmonary artery ANP were 116.3 ± 17.9 pg/ml during apnoea and 64.8 ± 15.2 pg/ml (P < 0.05) on nasal CPAP. 3. It is concluded that there is increased ANP release during sleep in patients with OSA and that CPAP treatment normalizes ANP secretion. These findings may explain previously identified urinary abnormalities in OSA.

1 December 1993 in SLEEP
Verified
Journal Article
Open access
PDF file
RDRoger T. Dean
Roger T. Dean
IWIan Wilcox
Ian Wilcox
Roger T. Dean, Ian Wilcox; Possible Atherogenic Effects of Hypoxia During Obstructive Sleep Apnea, Sleep, Volume 16, Issue suppl_8, 1 December 1993, Pages S15–